[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@avidresearch
"Maybe $RARE gets aquired if OI hits. $2.5-$3B /year sales with current pipeline and Angelman readout gives further upside. All that while trading at $3.8B valuation"
@avidresearch on X 2025-07-09 17:31:04 UTC 10.7K followers, 3348 engagements
"$WVE typically does earnings call in first week of Aug. July 30th is a bit early. We may see AATD updated multi-dose data with this ER" @avidresearch on X 2025-07-24 11:40:56 UTC 10.7K followers, 7210 engagements
"@JacobPlieth @ApexOnco Really sad to see how much time and energy was wasted on TIGIT" @avidresearch on X 2025-07-24 11:35:53 UTC 10.7K followers, XXX engagements
"@houndcl @jfais20 Yes INHBE has X commercialization pathways 1) mono 2) Post GLP1 weight maintenance 3) combo with low dose GLP1 $WVE" @avidresearch on X 2025-07-17 17:22:41 UTC 10.7K followers, XXX engagements
"@mikeconvente @A_May_MD SKYRIZI was at week XX 😀 so $ABVX achieves results faster and safer" @avidresearch on X 2025-07-22 21:21:25 UTC 10.7K followers, XXX engagements
"$ABVX went through @A_May_MD summary and as usual found it to be very compelling. Is market able to appreciate delta for clinical remission is for Week X (vs 12) while comparing topline results. Well established that remission rates increase over time" @avidresearch on X 2025-07-22 12:44:14 UTC 10.7K followers, 3636 engagements
"@DGTrading101 Bracing for a no-open today" @avidresearch on X 2025-07-22 22:23:16 UTC 10.7K followers, XXX engagements
"$WVE if INHBE weight loss at month X is just XX% of GLPs but has NO notable GI side effects (big if) is it still valuable as both mono-therapy and weight loss maintenance post GLP1 $LLY $NVO" @avidresearch on X 2025-07-17 15:24:00 UTC 10.7K followers, 9430 engagements
"@mikeconvente @A_May_MD Makes me think $abvx drug can sell $10B if chrons comes thru as well. Another benign AE drug except its oral" @avidresearch on X 2025-07-22 21:27:24 UTC 10.7K followers, XXX engagements
"This reminds me a bit of $BBIO month XX time point for overall survival while $ALNY used up to XX months" @avidresearch on X 2025-07-22 12:45:30 UTC 10.7K followers, 1006 engagements
"@plainyogurt21 @JinghangHu @jfais20 @AaronRosenblum5 @houndcl INHBE pace of fat loss will be slower than GLP1s so unlikely to be an issue" @avidresearch on X 2025-07-23 11:13:15 UTC 10.7K followers, XXX engagements
"Endoscopic improvement delta almost Rinvoq like but with cleaner safety. Cc @A_May_MD" @avidresearch on X 2025-07-22 20:12:25 UTC 10.7K followers, 3296 engagements
"@PikaCapital $gmab 2029 darzalex patent cliff" @avidresearch on X 2025-07-16 12:51:17 UTC 10.7K followers, XXX engagements
"Guys $abvx showed these impressive results at week X as @A_May_MD repeatedly pointed out vs recent ph2 trials that were using wk12 (or longer). Makes results that much more impressive" @avidresearch on X 2025-07-22 20:46:28 UTC 10.7K followers, 5788 engagements
"@A_May_MD The serious infection risk = placebo. Oral and clean safety = first line dominance" @avidresearch on X 2025-07-22 20:21:05 UTC 10.7K followers, 1011 engagements
"@A_May_MD Also begs question if $abvx should get some credit for chrons disease as well given compelling efficacy" @avidresearch on X 2025-07-22 20:21:54 UTC 10.7K followers, 1263 engagements
"@jfais20 $WVE INHBE will always have to a slower rate of weight loss than GLP1 (preclinical data 👇showing slower rate for INHBE) they can meet or exceed GLP-1 real world weight loss However they can outpace GLP1 weight loss estimand in real world by vastly higher compliance rate" @avidresearch on X 2025-07-17 17:04:23 UTC 10.7K followers, 1009 engagements